Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.

The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Boris Itkin, Agustin Garcia, Samanta Straminsky, Eduardo Daniel Adelchanow, Matias Pereyra, Gabriela Acosta Haab, Ariel Bardach
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ab8ebf92343e4ebdb6a4668c08a9319c
record_format dspace
spelling oai:doaj.org-article:ab8ebf92343e4ebdb6a4668c08a9319c2021-12-02T20:13:54ZPrevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.1932-620310.1371/journal.pone.0257976https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257976https://doaj.org/toc/1932-6203The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.Boris ItkinAgustin GarciaSamanta StraminskyEduardo Daniel AdelchanowMatias PereyraGabriela Acosta HaabAriel BardachPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257976 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Boris Itkin
Agustin Garcia
Samanta Straminsky
Eduardo Daniel Adelchanow
Matias Pereyra
Gabriela Acosta Haab
Ariel Bardach
Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
description The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.
format article
author Boris Itkin
Agustin Garcia
Samanta Straminsky
Eduardo Daniel Adelchanow
Matias Pereyra
Gabriela Acosta Haab
Ariel Bardach
author_facet Boris Itkin
Agustin Garcia
Samanta Straminsky
Eduardo Daniel Adelchanow
Matias Pereyra
Gabriela Acosta Haab
Ariel Bardach
author_sort Boris Itkin
title Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_short Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_full Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_fullStr Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_full_unstemmed Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
title_sort prevalence of her2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/ab8ebf92343e4ebdb6a4668c08a9319c
work_keys_str_mv AT borisitkin prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT agustingarcia prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT samantastraminsky prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT eduardodanieladelchanow prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT matiaspereyra prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT gabrielaacostahaab prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
AT arielbardach prevalenceofher2overexpressionandamplificationincervicalcancerasystematicreviewandmetaanalysis
_version_ 1718374728215822336